• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
ALEXMED ePosters
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 5 (2023)
Volume Volume 4 (2022)
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Volume Volume 1 (2019)
Aboulenein, W., Karkour, T., Abd Aldayem, T., Ragab, M. (2024). ROLE OF RESVERATROL IN THE TREATMENT OF PATIENTS WITH SEVERE PREECLAMPSIA. ALEXMED ePosters, 6(1), 49-50. doi: 10.21608/alexpo.2024.276360.1807
Wafaa Aboulenein; TAREK Abdelzaher Karkour; Tamer Abd Aldayem; Mohamed Mostafa Tawfik Ragab. "ROLE OF RESVERATROL IN THE TREATMENT OF PATIENTS WITH SEVERE PREECLAMPSIA". ALEXMED ePosters, 6, 1, 2024, 49-50. doi: 10.21608/alexpo.2024.276360.1807
Aboulenein, W., Karkour, T., Abd Aldayem, T., Ragab, M. (2024). 'ROLE OF RESVERATROL IN THE TREATMENT OF PATIENTS WITH SEVERE PREECLAMPSIA', ALEXMED ePosters, 6(1), pp. 49-50. doi: 10.21608/alexpo.2024.276360.1807
Aboulenein, W., Karkour, T., Abd Aldayem, T., Ragab, M. ROLE OF RESVERATROL IN THE TREATMENT OF PATIENTS WITH SEVERE PREECLAMPSIA. ALEXMED ePosters, 2024; 6(1): 49-50. doi: 10.21608/alexpo.2024.276360.1807

ROLE OF RESVERATROL IN THE TREATMENT OF PATIENTS WITH SEVERE PREECLAMPSIA

Article 1, Volume 6, Issue 1, January 2024, Page 49-50  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2024.276360.1807
View on SCiNiTO View on SCiNiTO
Authors
Wafaa Aboulenein1; TAREK Abdelzaher Karkour2; Tamer Abd Aldayem3; Mohamed Mostafa Tawfik Ragab email 4
1Obstetrics and Gynecology Department, Faculty of Medicine, Alexandria University, Egypt
2Obstetrics and Gynaecology department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
3Obstetric and Gynecology department, faculty of Medicine, Alexandria University, Alexandria
4Department of Obstetrics & Gynaecology, Faculty of Medicine, Alexandria University
Abstract
Preeclampsia is a multisystem progressive disorder characterized by the new onset of hypertension and proteinuria or the new onset of hypertension plus significant end-organ dysfunction with or without proteinuria, typically presenting after 20 weeks of gestation or postpartum. Incidence: About 4.6 % of pregnancies worldwide are complicated by preeclampsia. Variations in incidence reflect differences in the maternal age distribution and proportion of nulliparous patients in the population. The incidence is increasing, likely related to population-level increases in risk factors for the disease. According to severity, preeclampsia is classified into non severe and severe. Labetalol is a selective alpha blocker and a nonselective beta blocker that produces vasodilatation and results in a decrease in systemic vascular resistance. Resveratrol 3,5,40-trihydroxy-trans-stilbene an antioxidant polyphenolic compound found in various plants and foods including grapes. Resveratrol can induce uterine arteries relaxation during PE pathological events.
Aim of the work:
The present study was designed to evaluate the effect of adding Resveratrol to labetalol in the treatment of severe preeclampsia through assessment of changes in blood pressure and the time needed for adequate control of blood pressure before termination of pregnancy.
Keywords
RESVERATROL; SEVERE PREECLAMPSIA; TREATMENT
Supplementary Files
download 1807 20 (29).pdf
Statistics
Article View: 61
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.